Flow cytometry is an useful tool to study hematological diseases at diagnosis and after treatment. We study new plasma cells' surface antigens to improve the minimal residual disease study in multiple myeloma. Some of new antigens studied are very helpful after immunotherapy with monoclonal antibodies.
More than Just Lines on a Map: Best Practices for U.S Bike Routes
Presentazione workshop sies 2015 muccio
1. SUITABLE SURFACE ANTIGENS FOR
MYELOMA AND NORMAL PLASMA
CELLS IDENTIFICATION AFTER
MONOCLONAL ANTIBODIES
THERAPY.
Vittorio Emanuele Muccio
Divisione Universitaria di Ematologia
Prof. M. Boccadoro
A.O.U Città della Salute e della Scienza di
Torino
Vittorio Emanuele Muccio
8. EuroFlow panel for MM MRD study
Tube 1: CD138 CD27 CD38 CD56 CD45 CD19 CD117 CD81
Tube 2: CD138 CD27 CD38 CD56 CD45 CD19 cyIgKappa cyIgLambda
Vittorio Emanuele Muccio
9. 9th International Conference on
Human Leukocyte Differentiation Antigens (HLDA9)
82 Surface molecules
SIALOADESINES
SLAM
INTEGRINSTNF/TNFR
IRTA
CITOCHINES-R
CHEMOKINES-R CD28/B7TLR/C-TYPE LEC R
Vittorio Emanuele Muccio
10. # mAb Specificity Conjugated fluorochrome CD Isotype Ab Species % of positive MM
samples
20 FCRL1 PE CD307a IgG1k Mouse 0
21 FCRL2 PE CD307b IgG2Ak Mouse 0
22 FCRL3 PE CD307c IgG2Bk Mouse 0
23 FCRL4 PE CD307d IgG2Ak Mouse 0
28 Siglec-7 PE CD328 IgG1k Mouse 0
29 B7-2 PE CD86 IgG1k Mouse 64*
30 IL-10R PE CD210 IgG2ak Rat 0
31 CCR7 PE CD197 IgG2ak Rat 0
32 Siglec-9 PE CDw329 IgG1k Mouse 0
33 HB15 PE CD83 IgG1k Mouse 0
34 CTLA-4 PE CD152 IgG2ak Mouse 0
35 B7-1 PE CD80 IgG1k Mouse 0
36 IL6-Rα PE CD126 IgG1k Mouse 45
37 PD1 PE CD279 IgG1k Mouse 0
38 B7-DC PE CD273 IgG1k Mouse 0
39 IL-4Rα PE CD124 IgG1k Mouse 0
40 OX2 PE CD200 IgG1k Mouse 70*
41 gp130 PE CD130 IgG1k Mouse 45
42 IL-12R PE CD212 IgG1k Mouse 0
43 Siglec PE CD328 IgG1k Mouse 0
44 CCR2 A647 CD192 IgG2b Mouse 18
45 ICOS PE CD278 IgG1 Mouse 0
46 CXCR4 PE CD184 IgG2ak Mouse 64*
47 BTLA PE CD272 IgG1k Mouse 64*
48 CCR6 PE CD196 IgG1k Mouse 18
49 TACI PE CD267 IgG2ak Rat 0
50 CXCR5 A647 CD185 IgG2bk Rat 45
51 Integrin beta 7 chain PE NONE IgG2ak Rat 0
52 CCR1 A647 CD191 IgG2bk Mouse 27
53 Integrin beta 5 PE NONE IgG1 k Mouse 0
54 B7-H4 PE NONE IgG1 k Mouse 0
55 DR4 PE CD271 IgG1 k Mouse 0
56 CMKLR1 PE NONE IgG2a k Rat 0
57 DR5 PE CD262 IgG1 k Mouse 18
74 Integrin beta 6 PE NONE IgG2b Mouse 0
75 Dectin-1/CLEC7A PE NONE IgG2b Mouse 0
76 TREM-1 PE NONE IgG1 Mouse 10
77 Siglec-5/Siglec-14 APC CD170 IgG1 Mouse 0
78 AMICA PE NONE IgG2a Mouse 0
79 BLT1/LTB4R1 PE NONE IgG1 Mouse 10
80 Siglec-9 APC CD329 IgG2a Mouse 0
81 IL-23-R PE NONE IgG2b Mouse 9
82 Integrin alfaVbeta5 PE NONE IgG1 Mouse 0
83 CRTAM PE CD355 IgG2b Mouse 0
84 DCIR/CLEC4A PE NONE IgG1 Mouse 0
85 GITR PE NONE IgG1k Mouse 0
86 Ly9 PE CD229 IgG1k Mouse 100*
87 CRACC PE CD319 IgG2b k Mouse 100*
88 BLAST-1 PE CD48 IgG1k Mouse 100*
89 SLAMF5 PE CD84 IgG2a k Mouse 17
90 Toll-like Receptor 3 PE CD283 IgG2a k Mouse 0
91 DcR3 PE NONE IgG1k Mouse 9
92 DR3 (TRAMP) PE NONE IgG1k Mouse 0
93 NTBA PE NONE IgG1k Mouse 100*
94 HVEM PE CD270 IgG1k Mouse 45
95 TSLPR PE NONE IgG1k Mouse 0
96 TWEAK PE CD255 IgG3 k Mouse 0
97 TCL1 PE NONE IgG2b k Mouse 0
98 Galectin-3 (Mac-2) PE NONE IgG1k Mouse 0
99 GITR-L PE NONE IgG1k Mouse 0
100 Lymphotoxin beta receptor PE NONE IgG2b k Mouse 0
101 TREM-1 PE NONE IgG1k Mouse 0
106 SLAM PE CD150 IgG1k Mouse 67*
109 S1PR1 PE CD363 IgG2B Mouse 0
234 IL-15Ralfa PE NONE IgG2b k Mouse 0
235 BAFF-R PE CD268 IgG1 k Mouse 20
236 LIGHT PE CD258 IgG2b k Mouse 20
237 BAFF PE CD257 IgG1 k Mouse 40
238 CD274 PE CD274 IgG2b k Mouse 45
239 B7-H2 PE CD275 IgG2b k Mouse 20
240 CD267 PE CD267 IgG2a k Rat 20
241 NKG2D PE CD314 IgG1 Mouse 0
242 LAIR1 PE CD305 IgG2b Mouse 0
243 DEP-1 PE CD148 IgG1 Mouse 20
244 Syndecan-2 PE NONE IgG2b Rat 20
245 CXCR7/RDC-1 PE NONE IgG2a Mouse 0
246 IL21R PE NONE IgG1 Mouse 0
247 Toll-like Receptor 9 PE CD289 IgG2a k Rat 0
249 TACI PE CD267 IgG2a Mouse 40
250 ABCG2 PE CDw338 IgG2b k Mouse 0
251 BR3 PE CD268 IgG2a k Mouse 0
252 BLyS PE CD257 IgG1 k Mouse 0
In the right column the
percentage of positive
samples at diagnosis of
MM is reported.
Only antigens expressed
in >50% of patients were
selected for the second
phase of the study,
#
mAb
Specificity Conjugated
fluorochrome
CD Isotype Ab Species % of positive
MM samples
29 B7-2 PE CD86 IgG1k Mouse 64*
40 OX2 PE CD200 IgG1k Mouse 70*
46 CXCR4 PE CD184 IgG2ak Mouse 64*
47 BTLA PE CD272 IgG1k Mouse 64*
86 Ly9 PE CD229 IgG1k Mouse 100*
87 CRACC PE CD319 IgG2b k Mouse 100*
88 BLAST-1 PE CD48 IgG1k Mouse 100*
93 NTBA PE NONE IgG1k Mouse 100*
106 SLAM PE CD150 IgG1k Mouse 67*
TESTED ANTIBODIES
Vittorio Emanuele Muccio
11. 35 NEWLY DIAGNOSED MM 15 HEALTHY SUBJECTS
CD86 CD200 CD272 CD184
CD229 CD319 CD352 CD150
CD48
SECOND PHASE OF THE STUDY
Vittorio Emanuele Muccio
14. CONCLUSIONS
CD150, CD86, CD200 and CD352
allow the differentiation between healthy and tumor PCs
Useful in the MRD study after
therapy with Lorvotuzumab
(anti-CD56), Dacetuzumab or
Lucatumumab (anti-CD40)
CD352
Vittorio Emanuele Muccio
16. Useful to carachterize PCs
in the MRD study after
therapy with BT062 (anti-
CD138) or Daratumumab
(anti-CD38)
CONCLUSIONS
Vittorio Emanuele Muccio
17. A.O.U Città della Salute e della Scienza di
Torino
Divisione Universitaria di Ematologia
Prof. M. Boccadoro
Dott.ssa Paola Omedè
Gilestro Milena
Saraci Elona
Astolfi Monica
Oddolo Daniela
Caltagirone Simona
Ruggeri Marina
Marzanati Eleonora
Aschero Simona
Gattei Valter
Zucchetto Antonella
Vittorio Emanuele Muccio